

Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial

SUPPLEMENTARY MATERIALS

Supplementary Table 1: The relation between the expression levels of 127 genes and pathological response to either SC or PC. See Supplementary Table 1

Supplementary Table 2: Relation between mRNA expression and clinicopathological features (biomarker analysis cohort, $n = 46$)

Variables/categories	<i>ZDHHC14</i>			<i>TIMP1</i>			<i>CLDN18.2</i>		
	≥ 0.608 ($n = 31$)	< 0.608 ($n = 15$)	<i>P</i> -value	≥ 10.473 ($n = 8$)	≥ 10.473 ($n = 38$)	<i>P</i> -value	≥ 23.564 ($n = 18$)	< 23.564 ($n = 28$)	<i>P</i> -value
Age (years)									
< 67	20	8	0.4463	2	26	0.0022	9	9	0.2258
≥ 67	11	7		6	12		9	19	
Gender									
Male	22	11	0.8673	1	11	0.3356	13	21	0.8341
Female	9	4		7	27		5	7	
Histologic type									
Differentiated	13	5	0.5752	3	15	0.9172	7	11	0.9785
Undifferentiated	18	10		5	23		11	17	
Variables/categories	<i>EGFR</i>			<i>RRM1</i>			<i>MUC2</i>		
	≥ 0.549 ($n = 21$)	< 0.549 ($n = 25$)	<i>P</i> -value	≥ 0.803 ($n = 12$)	< 0.803 ($n = 34$)	<i>P</i> -value	≥ 14.04 ($n = 9$)	≥ 14.04 ($n = 37$)	<i>P</i> -value
Age (years)									
< 67	13	15	0.8951	5	23	0.1129	4	24	0.2603
≥ 67	8	10		7	11		5	13	
Gender									
Male	16	18	0.7472	8	26	0.5061	5	29	0.162
Female	5	7		4	8		4	8	
Histologic type									
Differentiated	9	9	0.9172	6	12	0.3695	3	15	0.6911
Undifferentiated	12	16		6	22		6	22	
Variables/categories	<i>DSG2</i>								
	≥ 4.312 ($n = 24$)	< 4.312 ($n = 22$)	<i>P</i> -value						
Age (years)									
< 67	9	19	0.2258						
≥ 67	9	9							
Gender									
Male	13	22	0.6222						
Female	5	6							
Histologic type									
Differentiated	7	11	0.9785						
Undifferentiated	11	17							

Supplementary Table 3: Relation between mRNA expression and clinicopathological features in pStage II/III gastric cancer (different cohort, $n = 253$). See Supplementary Table 3